Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren Alone and in Combination With Atenolol in Essential Hypertension
NCT00262236Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2005
- Primary completion
- Aug 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of aliskiren in essential hypertension (3 arms), sponsored by Novartis. Primary endpoint: Change from baseline in diastolic blood pressure at 12 weeks. Started Nov 2005; status: completed.
02
Drugs
aliskiren
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00262236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00262236.